Telatinib

DB15393InvestigationalSmall molecule

Telatinib is under investigation in clinical trial NCT03817411 (Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer).

Mechanism: Pharmacologically active on Vascular endothelial growth factor receptor 3, Platelet-derived growth factor receptor beta, and Vascular endothelial growth factor receptor 2
Curator reviewed
Formula / weight: C₂₀H₁₆ClN₅O₃ · 409.83 g/mol (avg)

Resolves to

Compound

UNII18P7197Q7JCAS332012-40-5ChEMBLCHEMBL2079588

Clinical / RWD

PharmGKBPA165980595

Structure

InChIKeyQFCXANHHBCGMAS-UHFFFAOYSA-NSMILESCNC(=O)C1=CC(COC2=C3OC=CC3=C(NC3=CC=C(Cl)C=C3)N=N2)=CC=N1

Targets

P35916FLT4P09619PDGFRBP35968KDRP10721KIT

What you can answer from here — as of June 15, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

15+ReferencesStructured and connected to the statements they support

Which drugs share a target with Telatinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account